ArticleJournal of cancer research and clinical oncology2022

Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.

Xuetian Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.